PT - JOURNAL ARTICLE AU - Wang, Bing AU - Andraweera, Prabha AU - Elliott, Salenna AU - Mohammed, Hassen AU - Lassi, Zohra AU - Twigger, Ashley AU - Borgas, Chloe AU - Gunasekera, Shehani AU - Ladhani, Shamez AU - Marshall, Helen Siobhan TI - Asymptomatic SARS-CoV-2 infection by age: A systematic review and meta-analysis AID - 10.1101/2022.05.05.22274697 DP - 2022 Jan 01 TA - medRxiv PG - 2022.05.05.22274697 4099 - http://medrxiv.org/content/early/2022/05/05/2022.05.05.22274697.short 4100 - http://medrxiv.org/content/early/2022/05/05/2022.05.05.22274697.full AB - Objectives This systematic review and meta-analysis aimed to estimate the age-specific proportion of asymptomatic SARS-CoV-2 infected persons by year of age.Methods We searched PubMed, Embase, medRxiv and Google Scholar on 10 September 2020 and 1 March 2021. We included studies conducted during January to October 2020, prior to routine vaccination against COVID-19. Since we expected the relationship between the asymptomatic proportion and age to be non-linear, multilevel mixed-effects logistic regression (QR decomposition) with a restricted cubic spline was used to model asymptomatic proportions as a function of age.Results A total of 38 studies were included in the meta-analysis. In total, 6556 out of 14850 cases were reported as asymptomatic. The overall estimate of the proportion of people who became infected with SARS-CoV-2 and remained asymptomatic throughout infection was 44.1% (6556/14850, 95%CI 43.3%-45.0%). The asymptomatic proportion peaked in adolescents (36.2%, 95%CI 26.0%-46.5%) at 13.5 years, gradually decreased by age and was lowest at 90.5 years of age (8.1%, 95%CI 3.4%-12.7%).Conclusions Given the high rates of asymptomatic carriage in adolescents and young adults and their active role in virus transmission in the community, heightened vigilance and public health strategies are needed among these individuals to prevent disease transmission.Competing Interest StatementH.S.M. is an investigator on vaccine trials sponsored by the GSK group of companies, Pfizer, Sanofi, and Merck. The institution, which H.S.M., B.W., P.A., and H.M. are employed with, receives funding for investigator-led studies from industry, including Pfizer and Sanofi Pasteur; H.S.M., B.W., P.A., and H.M. receive no personal payments from industry. Others have no potential conflicts of interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This is a systematic review and meta-analysis. Only published data was used.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.